Intercept Pharmaceuticals, Inc. (ICPT) News

Intercept Pharmaceuticals, Inc. (ICPT): $19.00

0.04 (+0.21%)

POWR Rating

Component Grades








Add ICPT to Watchlist
Sign Up

Industry: Biotech




#32 of 351

in industry

Filter ICPT News Items

ICPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ICPT News Highlights

  • ICPT's 30 day story count now stands at 4.
  • Over the past 29 days, the trend for ICPT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BEAT, EYE and MDGL are the most mentioned tickers in articles about ICPT.

Latest ICPT News From Around the Web

Below are the latest news stories about INTERCEPT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 31, 2023

Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now

Overbought stocks are an early indication of a potential correction on a stock; act now if you hold these stocks.

Rick Orford on InvestorPlace | October 19, 2023

Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years ago

It is a pleasure to report that the Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) is up 67% in the last quarter. But...

Yahoo | October 11, 2023

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.

Yahoo | October 2, 2023

Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data

Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.

Yahoo | September 28, 2023

Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal

Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.

Yahoo | September 27, 2023

Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?

Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | September 27, 2023

Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?

Although Intercept Pharmaceuticals popped higher on a buyout deal, many stakeholders of ICPT stock are left wondering what might have been.

Josh Enomoto on InvestorPlace | September 26, 2023

Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.

Yahoo | September 26, 2023

UPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mln

Italy's Alfasigma S.p.A agreed on Tuesday to buy drugmaker Intercept Pharmaceuticals for $794 million as it aims to expand its treatment portfolio in liver diseases and digestive system disorders, and bolster presence in the U.S. The proposed all-cash acquisition would add Intercept's Ocaliva, a treatment for liver disease primary biliary cholangitis, to Alfasigma's portfolio. Alfasigma's acquisition of Intercept and its drug Ocaliva makes "best economic cost sense" given that a larger company can market and commercialize the drug with better margins and scale than a smaller biotech, Jefferies analyst Michael Yee said.

Yahoo | September 26, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!